Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
Status:
Withdrawn
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This study were designed to verify the better method of survival for metastatic ICC. Since
the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN
guideline), our previous study found similar results from FOLFOX (second-line treatment from
NCCN guideline) compared with GEMOX.
Our current study were conducted for further investigation to verify the better method for
metastatic ICC.